Salīdzināt metodes

	Anketas par apmierinātību ar ārstēšanu medikamentiem (TSQM)	Zāļu attieksmes inventārs (DAI)
Nozare	Farmakoloģija	Farmakoloģija
Saime	Process / pipeline	Process / pipeline
Izcelsmes gads	2004	1983
Autors	Mary Jo Atkinson and colleagues	Thomas P. Hogan, Ahmed G. Awad, and Robert Eastwood
Tips	Self-report	Self-report
Pirmavots	Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Berman, B. M., & Wolpert, B. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel of chronically ill individuals. Health and Quality of Life Outcomes, 2(1), 12.	Hogan, T. P., Awad, A. G., & Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine, 13(1), 177-183.
Citi nosaukumi	TSQM	DAI, DAI-10, DAI-30
Saistītās	4	4
Kopsavilkums	The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item generic measure developed by Atkinson and colleagues in 2004 to assess patient satisfaction with medication across diverse therapeutic areas and disease conditions. It measures four key dimensions—Effectiveness, Side Effects, Convenience, and Global Satisfaction—with standardized 0–100 scoring, making it suitable for cross-disease comparison and health economic evaluation. The TSQM has become a standard outcome in pharmaceutical research, clinical trials, and real-world medication effectiveness studies.	The Drug Attitude Inventory (DAI) is a brief self-report measure developed by Hogan, Awad, and Eastwood in 1983 to assess attitudes toward medication and predicted medication compliance in schizophrenia and other psychiatric conditions. The original 30-item version (DAI-30) and the widely used 10-item short form (DAI-10) capture patients' subjective experience of medication benefit, side effects, and overall willingness to take medication as a predictor of adherence. The DAI is particularly valuable in psychiatric care, where attitudes toward antipsychotic and antidepressant medications strongly predict adherence and clinical outcomes.